ID

39256

Description

ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.; ODM derived from: https://clinicaltrials.gov/show/NCT01774721

Link

https://clinicaltrials.gov/show/NCT01774721

Keywords

  1. 12/13/19 12/13/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

December 13, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility EGFR Positive Non-small Cell Lung Cancer NCT01774721

Eligibility EGFR Positive Non-small Cell Lung Cancer NCT01774721

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
evidence of histo or cytopathology confirmed, advanced nsclc (with known histology) with the presence of egfr activating mutation (exon 19 deletion or the l858r mutation in exon 21).
Description

Non-Small Cell Lung Carcinoma Advanced | EGFR Activating Mutation | EGFR exon 19 deletion | Point mutation in exon 21 (L858R)

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0205179
UMLS CUI [2]
C2984891
UMLS CUI [3]
C3889117
UMLS CUI [4]
C3888903
it is acceptable for subjects with the presence of the exon 20 t790m mutation together with either egfr activating mutation (exon 19 deletion or the l858r mutation in exon 21) to be included in this study
Description

EGFR Exon 20 Mutation | EGFR Activating Mutation | EGFR exon 19 deletion | Point mutation in exon 21 (L858R)

Data type

boolean

Alias
UMLS CUI [1]
C4289655
UMLS CUI [2]
C2984891
UMLS CUI [3]
C3889117
UMLS CUI [4]
C3888903
minimum of 12 months disease free interval between completion of systemic therapy and recurrence of nsclc
Description

Systemic therapy Complete | Disease Free Duration | Non-small cell lung cancer recurrent

Data type

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0205197
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0332296
UMLS CUI [2,3]
C0449238
UMLS CUI [3]
C0278517
adequate tissue sample must be available for central analyses.
Description

Availability of Tissue specimen | Analysis

Data type

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C1292533
UMLS CUI [2]
C0002778
adequate renal, hematologic, liver function.
Description

Renal function | Hematologic function | Liver function

Data type

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0221130
UMLS CUI [3]
C0232741
ecog ps of 0-1.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
radiologically measurable disease.
Description

Measurable Disease Radiologic

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C0205483
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.
Description

Small cell carcinoma of lung | Carcinoid tumor of lung

Data type

boolean

Alias
UMLS CUI [1]
C0149925
UMLS CUI [2]
C0280089
any other mutation other than exon 19 deletion or l858r in exon 21, with or without the presence of the exon 20 t790m mutation.
Description

Mutation | Exception EGFR exon 19 deletion | Exception Point mutation in exon 21 (L858R) | EGFR Exon 20 Mutation | EGFR Exon 20 Mutation Absent

Data type

boolean

Alias
UMLS CUI [1]
C0026882
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C3889117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C3888903
UMLS CUI [4]
C4289655
UMLS CUI [5,1]
C4289655
UMLS CUI [5,2]
C0332197
any history of brain mets or leptomeningeal mets.
Description

Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges

Data type

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C1704231
any previous anti-cancer systemic treatment of early, locally advanced, or metastatic nsclc.
Description

Systemic therapy Non-Small Cell Lung Carcinoma Early stage | Systemic therapy Non-Small Cell Lung Carcinoma Advanced Locally | Systemic therapy Non-small cell lung cancer metastatic

Data type

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0007131
UMLS CUI [1,3]
C2363430
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C0007131
UMLS CUI [2,3]
C0205179
UMLS CUI [2,4]
C1517927
UMLS CUI [3,1]
C1515119
UMLS CUI [3,2]
C0278987
uncontrolled medical disorders.
Description

Disease Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205318

Similar models

Eligibility EGFR Positive Non-small Cell Lung Cancer NCT01774721

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma Advanced | EGFR Activating Mutation | EGFR exon 19 deletion | Point mutation in exon 21 (L858R)
Item
evidence of histo or cytopathology confirmed, advanced nsclc (with known histology) with the presence of egfr activating mutation (exon 19 deletion or the l858r mutation in exon 21).
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C2984891 (UMLS CUI [2])
C3889117 (UMLS CUI [3])
C3888903 (UMLS CUI [4])
EGFR Exon 20 Mutation | EGFR Activating Mutation | EGFR exon 19 deletion | Point mutation in exon 21 (L858R)
Item
it is acceptable for subjects with the presence of the exon 20 t790m mutation together with either egfr activating mutation (exon 19 deletion or the l858r mutation in exon 21) to be included in this study
boolean
C4289655 (UMLS CUI [1])
C2984891 (UMLS CUI [2])
C3889117 (UMLS CUI [3])
C3888903 (UMLS CUI [4])
Systemic therapy Complete | Disease Free Duration | Non-small cell lung cancer recurrent
Item
minimum of 12 months disease free interval between completion of systemic therapy and recurrence of nsclc
boolean
C1515119 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0332296 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
C0278517 (UMLS CUI [3])
Availability of Tissue specimen | Analysis
Item
adequate tissue sample must be available for central analyses.
boolean
C0470187 (UMLS CUI [1,1])
C1292533 (UMLS CUI [1,2])
C0002778 (UMLS CUI [2])
Renal function | Hematologic function | Liver function
Item
adequate renal, hematologic, liver function.
boolean
C0232804 (UMLS CUI [1])
C0221130 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
ECOG performance status
Item
ecog ps of 0-1.
boolean
C1520224 (UMLS CUI [1])
Measurable Disease Radiologic
Item
radiologically measurable disease.
boolean
C1513041 (UMLS CUI [1,1])
C0205483 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Small cell carcinoma of lung | Carcinoid tumor of lung
Item
any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.
boolean
C0149925 (UMLS CUI [1])
C0280089 (UMLS CUI [2])
Mutation | Exception EGFR exon 19 deletion | Exception Point mutation in exon 21 (L858R) | EGFR Exon 20 Mutation | EGFR Exon 20 Mutation Absent
Item
any other mutation other than exon 19 deletion or l858r in exon 21, with or without the presence of the exon 20 t790m mutation.
boolean
C0026882 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C3889117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C3888903 (UMLS CUI [3,2])
C4289655 (UMLS CUI [4])
C4289655 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges
Item
any history of brain mets or leptomeningeal mets.
boolean
C0220650 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Systemic therapy Non-Small Cell Lung Carcinoma Early stage | Systemic therapy Non-Small Cell Lung Carcinoma Advanced Locally | Systemic therapy Non-small cell lung cancer metastatic
Item
any previous anti-cancer systemic treatment of early, locally advanced, or metastatic nsclc.
boolean
C1515119 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C2363430 (UMLS CUI [1,3])
C1515119 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
C0205179 (UMLS CUI [2,3])
C1517927 (UMLS CUI [2,4])
C1515119 (UMLS CUI [3,1])
C0278987 (UMLS CUI [3,2])
Disease Uncontrolled
Item
uncontrolled medical disorders.
boolean
C0012634 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial